biotech groups developing CVG206 and ZOSAL

Cevidra is a French pharmaceutical company specializing in the development and distribution of treatments for rare diseases and emergency situations, particularly in the field of NRBC (Nuclear, Radiological, Biological, and Chemical) risks. The company is notably developing CVG206, an innovative oral chelating agent designed to treat internal contamination by actinides such as plutonium and americium. Additionally, Cevidra offers ZOSAL, a specialized spray for the decontamination of skin and wounds exposed to chemical or radioactive substances. The firm operates as both a developer of proprietary emergency medicines and a distributor for orphan drugs in the European market. Cevidra maintains strong ties with the French military and atomic energy commissions to address public health threats.